| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands [F. B., A. P. M. J., A. R., M. v. G.]; Departments of Medical Oncology [H. J. B.], Pathology [G. L. S.], and Human Genetics, Free University of Amsterdam, 1007 MC Amsterdam, The Netherlands [A. W. M. N., H. J.]; Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and The Children's Hospital, Boston, Massachusetts 02115 [R. J. A.]; and Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts [D. H.]
Two different mechanisms that contribute to multidrug resistance (MDR) were found in derivatives of the human squamous lung cancer cell line SW-1573. The parental cell line has a low amount of mdr1 P-glycoprotein mRNA. In three independent selections for doxorubicin resistance, MDR variants arose in which mdr1 P-glycoprotein mRNA and protein was not detectable. Selection on higher doxorubicin concentrations gave rise to variants containing high levels of mdr1 mRNA, due to transcriptional activation of the mdr1 gene. Upon continued selection for higher levels of doxorubicin resistance, the mdr1 gene became amplified, resulting in an additional increase in the level of mdr1 mRNA. The cross-resistance pattern of the sublines that lack mdr1 P-glycoprotein expression is different from that seen in the mdr1 overexpressing cells. Both types of MDR cell lines are resistant to doxorubicin, daunorubicin, etoposide, colchicine, gramicidin D, and vincristine. However, in the non-P-glycoprotein-mediated MDR cell lines, resistance levels are lower and a preferential resistance for etoposide is seen.
1 This work was supported by The Netherlands Organization for Scientific Research (F. B.), the Charles H. Hood Foundation (R. J. A.), USPHS Grant CA17575 (D. H.), and Bristol-Myers (H. J. B.).
2 To whom requests for reprints should be addressed.
Received 11/17/89.
Revised 5/ 4/90.
This article has been cited by other articles:
|
|
 |
|
  R. van de Ven, M. C. de Jong, A. W. Reurs, A. J. N. Schoonderwoerd, G. Jansen, J. H. Hooijberg, G. L. Scheffer, T. D. de Gruijl, and R. J. Scheper Dendritic Cells Require Multidrug Resistance Protein 1 (ABCC1) Transporter Activity for Differentiation J. Immunol., May 1, 2006; 176(9): 5191 - 5198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. van den Heuvel-Eibrink, E. A. C. Wiemer, M. J. de Boevere, B. van der Holt, P. J. M. Vossebeld, R. Pieters, and P. Sonneveld MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia Blood, June 1, 2001; 97(11): 3605 - 3611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kool, M. v. d. Linden, M. de Haas, F. Baas, and P. Borst Expression of Human MRP6, a Homologue of the Multidrug Resistance Protein Gene MRP1, in Tissues and Cancer Cells Cancer Res., January 1, 1999; 59(1): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. M. Smit, F. Baas, J. E. Hoogendijk, G. H. Jansen, M. A. van der Valk, A. H. Schinkel, A. J. M. Berns, D. Acton, K. Nooter, H. Burger, et al. Peripheral Neuropathy in Mice Transgenic for a Human MDR3 P-Glycoprotein Mini-Gene J. Neurosci., October 15, 1996; 16(20): 6386 - 6393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Sardini, G. Mintenig, M. Valverde, F. Sepulveda, D. Gill, S. Hyde, C. Higgins, and P. McNaughton Drug efflux mediated by the human multidrug resistance P-glycoprotein is inhibited by cell swelling J. Cell Sci., January 12, 1994; 107(12): 3281 - 3290. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
